Gender differences in cardiotoxicities associated with immune checkpoint inhibitor therapy in cancer patients
Background: Immune checkpoint inhibitors (ICIs) are increasingly being used for cancer therapy. Cardiotoxicity from ICIs has largely been underestimated since cardiovascular monitoring is not routinely performed after initiating immunotherapy. Cardiotoxic side effects are uncommon but are serious co...
Main Authors: | Sheharyar Minhas, Ahmed Minhas, Maira Malik |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Journal of Clinical and Preventive Cardiology |
Subjects: | |
Online Access: | http://www.jcpconline.org/article.asp?issn=2250-3528;year=2020;volume=9;issue=2;spage=73;epage=77;aulast=Minhas |
Similar Items
-
Cardiotoxicity of checkpoint inhibitors: focus on immune side effects
by: Yuri I. Buziashvili, et al.
Published: (2024-04-01) -
Immune Checkpoint Inhibitors—Associated Cardiotoxicity
by: Chenghui Li, et al.
Published: (2022-02-01) -
The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
by: Inbar Nardi Agmon, et al.
Published: (2022-02-01) -
Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
by: Lu Gan, et al.
Published: (2022-08-01) -
Advances in immune checkpoint inhibitors induced-cardiotoxicity
by: Xiang Li, et al.
Published: (2023-02-01)